Metabolic Modifiers and Surveillance Strategies in HBV: Epidemiologic Insights and Global Elimination Goals

Nov 09 2025
Convention Center: Ballroom A, Level 3
2:00 PM - 3:30 PM

World Class Speakers

JJ
Moderator

Janice Jou, MD, MHS, FAASLD
Adnan Said, MD, MS, FAASLD
Moderator

Adnan Said, MD, MS, FAASLD

University of Wisconsin School of Medicine and Public Health

Description

This session will examine the intersection of chronic hepatitis B with metabolic risk factors, pharmacologic exposures, and evolving biomarkers in liver disease progression and surveillance. Topics will include the protective association of statins with HCC risk, the impact of hepatitis B on fibrosis in MASLD and impact of GLP-1 on outcomes in HBV. Additional talks will address the potential for HBsAg quantification to define thresholds for discontinuing HCC surveillance and global progress toward HBV elimination targets

Objectives

  • Evaluate the impact of statins, and MASLD on HBV disease progression and hepatocellular carcinoma risk
  • Assess how HBsAg quantification and metabolic comorbidities such as MASLD may refine fibrosis staging and HCC surveillance decisions in chronic HBV
  • Describe current epidemiologic trends and global efforts toward HBV elimination, including implications for surveillance and care strategies in diverse populations